Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Alaska Alliance for Community Engagement Phase II: Partnership for Action Toward Health (AK ACE-PATH)

30 de agosto de 2026 actualizado por: University of Alaska Fairbanks

Alaska Alliance for Community Engagement Phase II: Protecting Health in the American Arctic: Implementing Localized Solutions to Promote Health and Prevent Chronic Disease in Rural Alaska

The AK ACE-PATH Phase II study aims to pilot and implement a novel intervention, Tools for Arctic Health Promotion (TAHP), to address Alaska Native (AN) community priorities related to local health and community-level resilience.

Descripción general del estudio

Descripción detallada

In Phase I of AK ACE, community partners identified and prioritized local stressors through a consensus-based process. Building on these findings, Phase II will implement interventions targeting the highest-priority stressors through modules designed to improve health outcomes.This study addresses a critical gap in understanding local health and mental health among AN populations facing rapid social change and overlapping public health challenges. The project focuses on developing community-driven solutions to improve physiological and mental health, particularly among youth, and to prevent chronic disease across the lifespan in rural Alaska. To achieve these goals, the study will develop and implement Tools for Arctic Health Promotion (TAHP), a novel intervention integrating data-driven tools and evidence-based community strategies. TAHP will support structured community engagement and deliver manualized health activities to approximately 410 adults and youth across five rural AN communities. The TAHP intervention will be evaluated through a feasibility pilot in one community and a paired dynamic waitlisted design (DWLD) across four additional communities. Behavioral and biological measures will assess individual- and community-level impacts on chronic disease prevention and mental health promotion.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

360

Fase

  • Fase 1

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Stacy Rasmus, PhD
  • Número de teléfono: 907-328-8919
  • Correo electrónico: smrasmus@alaska.edu

Copia de seguridad de contactos de estudio

  • Nombre: Hannah Robinson, MPH
  • Número de teléfono: 731-400-3539
  • Correo electrónico: hrobinson3@alaska.edu

Ubicaciones de estudio

    • Alaska
      • Fairbanks, Alaska, Estados Unidos, 99775
        • University of Alaska Fairbanks
        • Contacto:

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

  • Niño
  • Adulto
  • Adulto Mayor

Acepta Voluntarios Saludables

Sí

Descripción

Inclusion Criteria:

  • Self-identify as a permanent resident of the study community
  • Be a youth between the ages of 12-17 years or an adult 18+
  • Be able to provide written informed consent

Exclusion Criteria:

  • Does not have permanent residence in the community or has lived in the community less than 5 years
  • Is unable to provide written informed consent

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Prevención
  • Asignación: N / A
  • Modelo Intervencionista: Asignación de un solo grupo
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Enrollment in TAHP
The study will enroll 360 participants from four unique community settings to receive the TAHP intervention. The study design will make use of a dynamic wait-listed design (DWLD) with 360 participants assessed with behavioral and community-level measures at four time points: baseline (B), intervention midpoint (T1), Intervention end (T2) and 12-month follow-up (T3).
The TAHP intervention will utilize a valid measure of rural AN community-level protective factors (Allen, et al., 2025), and an evidence-based toolkit containing strategies proven to increase mental health and well-being in rural AN communities (Allen, Charles, et al., 2023). A formalized community engaged process will generate new intervention activities that integrate cutting-edge science to address local health priorities.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Perceived Stress Scale Questionnaire will measure individual-level indicators of stress that we hypothesize will decrease over time with intervention participation
Periodo de tiempo: Day 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)
The NIH Toolbox Perceived Stress Scale is a standardized tool designed to assess how unpredictable, uncontrollable, and overloaded individuals feel in their lives. We will analyze how individual stress indicators are mitigated over time by intervention participation.
Day 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)
General Life Satisfaction Scale will measure individual level indicators of life satisfaction that we hypothesize will increase with intervention participation
Periodo de tiempo: Day 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)
The NIH Toolbox General Life Satisfaction Scale is a tool designed to assess an individual's cognitive evaluation of their life experiences and overall satisfaction. We will assess how the intervention mitigates life satisfaction with individuals who participate.
Day 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)
We will assess if depression decreases with intervention participation using the PHQ-9 Questionnaire
Periodo de tiempo: Day 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)
The Patient Health Questionnaire 9 (PHQ-9) measures the frequency of depressed mood and anhedonia over the past two weeks. We will assess how the intervention impacts depressive symptoms with individual participation.
Day 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)
We will assess if anxiety symptoms decrease with intervention participation using the GAD-7
Periodo de tiempo: Day 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)
The Generalized Anxiety Disorder 7-Item (GAD-7) Screener will be given at every time point to assess how the intervention mitigates anxiety with individual participants
Day 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)
We will assess if food security increases using the food security index from the PhenX Toolkit
Periodo de tiempo: Day 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)
The PhenX Toolkit includes standardized measures for assessing food security, which is crucial for understanding social determinants of health. We will use items from the standardized food security tools to evaluate how food access impacts health outcomes and if food security increases with individual participation in the intervention.
Day 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)
We will assess if cultural efficacy increases with individual intervention participation using the Cultural Efficacy Scale.
Periodo de tiempo: Day 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)
The Cultural Efficacy Scale developed by Gonzalez, Sittner, and Walls in 2022 measures individuals' comfort and access to cultural and traditional resources, particularly within Indigenous communities. This scale consists of 7-8 items, each with a range of response options from "strongly disagree" to "strongly agree." We will analyze the data to link cultural efficacy with mental health outcomes (depression and anxiety), highlighting the protective effects of engagement in the intervention.
Day 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)
We will assess how the intervention increases individual protective factors using the Multi-Cultural Mastery Scale
Periodo de tiempo: Day 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)
The Multicultural Mastery Scale, developed by Allen and Mohatt, assesses coping strategies through self-mastery and communal mastery dimensions. It includes subscales that differentiate between mastery related to family and friends, highlighting the importance of social networks. We will utilize data from this scale to determine how the intervention increases positive coping and builds social networks connections in individuals who participate.
Day 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)
We will assess how intervention participation increases social and cultural connectedness using the Awareness of Connectedness Scale
Periodo de tiempo: Day 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)
The Awareness of Connectedness Scale (ACS), developed by Mohatt and Fok, measures an individual's awareness of their interrelatedness with family, community, and the natural environment. This scale is particularly focused on cultural aspects of wellness and healing among Alaska Native people, providing insights into their social and ecological connections. We will utilize data from the scale to assess the intervention impacts on building connectedness among individual participants.
Day 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)
We will assess how the intervention increases reasons for life and meaning and purpose using the Reasons for Life Scale
Periodo de tiempo: Day 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)
The Reasons for Life Scale (RFL), developed by Allen and Rasmus, focuses on cultural strengths and protective factors against suicide, particularly among Alaska Native people. It emphasizes resilience, cultural teachings, and community recognition as vital components in promoting mental health and preventing suicide. We will utilize data from scale to assess how the intervention promotes reasons for life and associates with mental health outcomes (depression and anxiety) in individuals who participate in activities.
Day 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
We will assess the increase in community-level factors that are protective and contribute to health outcomes using the Protective Community Scale
Periodo de tiempo: Day 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)
The Protective Community Scale (PCS), developed by Wexler, Allen, and Rasmus, aims to identify community-level protective factors that can reduce suicide risk among Alaska Native youth. This scale is part of a broader effort to enhance resilience in these communities through culturally relevant measures and community engagement. We will analyze data from the PCS to determine if the intervention has mitigated environmental stressors and increased community protection.
Day 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)

Otras medidas de resultado

Medida de resultado
Medida Descripción
Periodo de tiempo
We will assess changes to a stress biomarker, cortisol, using Salimetrics OnTimePoint SalivaTM Collection Management application system.
Periodo de tiempo: Day 1 (baseline), 8 months (T2) and at 20 months (T3)
To measure the impacts of our intervention on biological outcomes, we will assess biomarkers associated with allostatic load - cortisol as an indicator of physiological stress response. These biomarkers will allow us to evaluate whether participation in the intervention is associated with reduced chronic stress burden and improved mental health (anxiety and depression) over time. Our proposed saliva collection protocol will involve our research team members administering the saliva kits with youth and adult participants over a 3-day period with multiple tests to capture cortisol levels throughout the day. Multi-day cortisol levels will be averaged to determine a baseline, and the same process will be used for saliva collection and measurement of cortisol levels at each time point.
Day 1 (baseline), 8 months (T2) and at 20 months (T3)

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

21 de septiembre de 2026

Finalización primaria (Estimado)

31 de octubre de 2028

Finalización del estudio (Estimado)

30 de abril de 2029

Fechas de registro del estudio

Enviado por primera vez

25 de agosto de 2026

Primero enviado que cumplió con los criterios de control de calidad

30 de agosto de 2026

Publicado por primera vez (Actual)

3 de septiembre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

3 de septiembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

30 de agosto de 2026

Última verificación

1 de agosto de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir